Trials / Completed
CompletedNCT00503711
Phase I Chinese PK
An Open Label, Phase I, Rising Multiple Dose, Single Centre Study to Determine the PK and Tolerability of ZD6474 at Different Dose Levels in Chinese Patients With Solid Malignancy Tumor
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vandetanib | 100 mg every other day, 100mg once daily |
| DRUG | Vandetanib 300 mg | 300mg once daily |
Timeline
- Start date
- 2006-09-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2007-07-19
- Last updated
- 2016-08-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00503711. Inclusion in this directory is not an endorsement.